We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0HL9 market cap is 374.98M. The company's latest EPS is EUR -7.0630 and P/E is -0.39.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 21.68M | 28.99M | 41.68M | 42.77M | 12.97M |
| Operating Income | -32.38M | -34.72M | -64.03M | -88.12M | -106.66M |
| Net Income | -32.37M | -41.37M | -57.52M | -86M | -105.94M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 112.36M | 175.73M | 225.14M | 200.51M | 97.16M |
| Total Liabilities | 73.69M | 103.73M | 89.18M | 47.6M | 39.35M |
| Total Equity | 38.67M | 71.99M | 135.95M | 152.92M | 57.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -29.06M | -19.4M | -86.59M | -104.89M | -110.27M |
| Investing | 4.34M | 8.01M | -3.85M | 5.61M | -36.06M |
| Financing | 26.04M | 69.25M | 133.58M | 88.56M | -6.22M |
| Market Cap | 374.98M |
| Price to Earnings Ratio | -0.39 |
| Price to Sales Ratio | 3.14 |
| Price to Cash Ratio | 1.06 |
| Price to Book Ratio | 0.71 |
| Dividend Yield | - |
| Shares Outstanding | 15M |
| Average Volume (1 week) | 2.65k |
| Average Volume (1 Month) | 2.47k |
| 52 Week Change | 0.00% |
| 52 Week High | 25.00 |
| 52 Week Low | 25.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Affimed Nv |
| Address |
gottlieb-daimler-strabe 2 mannheim 68165 |
| Website | https://www.affimed.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
